NL-OMON22341尚未招募不适用
Dose reduction of the new generation biologicals (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- Radboudumc
- 入组人数
- 244
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Plaque psoriasis (primarily)
- •Treatment for at least 6 months with IL23 or IL17 inhibitor in a normal dose (dose advised by the label)
- •PASI= 5 at inclusion and in previous 6 months (if no PASI scores are available, it should be clear from the patient record that psoriasis was clear/almost clear in previous 6 months).
- •DLQI = 5 at inclusion
排除标准
- •Another indication than plaque psoriasis as the main indication for biologic use (e.g. patient receives biologic for rheumatoid arthritis as the main indication).
- •Concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc).
- •Severe comorbidities with short life-expectancy (e.g. metastasized tumor).
- •Presumed inability to follow the study protocol.
研究者
相似试验
进行中（未招募）
1 期
Dose reduction of IL17 and IL23 inhibitors for psoriasispsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10037155Term: Psoriasis and similar disordersSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-004230-42-NLRadboudumc244
尚未招募
不适用
Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio studyNL-OMON29024ZonMw, KCE244
招募中
4 期
Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio studyNL-OMON52624Academisch Medisch Centrum142
进行中（未招募）
1 期
Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trialEUCTR2017-001970-41-DKMD, PhD Salome Kristensen180
进行中（未招募）
1 期
Dose decrease of biologics for psoriasisAdult Patients diagnosed psoriasis vulgarisMedDRA version: 18.1Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10015581Term: Exacerbation of psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10037155Term: Psoriasis and similar disordersSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 18.1Level: LLTClassification code 10037156Term: Psoriasis flare-upSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2015-000943-17-NLRadboudumc120